WO2023106881A1 - 암세포 성장 억제 효과를 나타내는 신규 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약학 조성물 - Google Patents
암세포 성장 억제 효과를 나타내는 신규 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약학 조성물 Download PDFInfo
- Publication number
- WO2023106881A1 WO2023106881A1 PCT/KR2022/020021 KR2022020021W WO2023106881A1 WO 2023106881 A1 WO2023106881 A1 WO 2023106881A1 KR 2022020021 W KR2022020021 W KR 2022020021W WO 2023106881 A1 WO2023106881 A1 WO 2023106881A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- group
- phenyl
- amino
- alkyl group
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 41
- 201000011510 cancer Diseases 0.000 title claims description 40
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 17
- 150000003230 pyrimidines Chemical class 0.000 title abstract description 7
- 230000002401 inhibitory effect Effects 0.000 title description 10
- 230000010261 cell growth Effects 0.000 title description 5
- 230000001747 exhibiting effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 30
- -1 heterocyclic pyrimidine derivative Chemical class 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 230000003463 hyperproliferative effect Effects 0.000 claims abstract description 16
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims abstract description 13
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 47
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 46
- 125000000217 alkyl group Chemical group 0.000 claims description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 239000001257 hydrogen Substances 0.000 claims description 40
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- 230000035772 mutation Effects 0.000 claims description 23
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 16
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 16
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 230000002018 overexpression Effects 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 239000003183 carcinogenic agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000008334 Dermatofibrosarcoma Diseases 0.000 claims description 2
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000002071 myeloproliferative effect Effects 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 43
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 7
- 229960005061 crizotinib Drugs 0.000 description 7
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 7
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- YWPHBSHEGTZPNS-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)C)C=1CCN(CC=1)C1CCOCC1)OC(C)C)NC1=C(C=CC=C1)S(=O)(=O)C(C)C Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)C)C=1CCN(CC=1)C1CCOCC1)OC(C)C)NC1=C(C=CC=C1)S(=O)(=O)C(C)C YWPHBSHEGTZPNS-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- YPMKIXADVWKELK-UHFFFAOYSA-N n-(2-aminophenyl)-n-methylmethanesulfonamide Chemical compound CS(=O)(=O)N(C)C1=CC=CC=C1N YPMKIXADVWKELK-UHFFFAOYSA-N 0.000 description 2
- MXWUQRNCQCAURO-UHFFFAOYSA-N n-methyl-n-(2-nitrophenyl)methanesulfonamide Chemical compound CS(=O)(=O)N(C)C1=CC=CC=C1[N+]([O-])=O MXWUQRNCQCAURO-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000008261 resistance mechanism Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000011519 second-line treatment Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- NAIHRQRGVKYAIV-UHFFFAOYSA-N tert-butyl 4-(2-methyl-4-nitro-5-propan-2-yloxyphenyl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(C=2CCN(CC=2)C(=O)OC(C)(C)C)=C1C NAIHRQRGVKYAIV-UHFFFAOYSA-N 0.000 description 2
- URNIKKBMSGLWFT-UHFFFAOYSA-N tert-butyl 4-(5-fluoro-2-methyl-4-nitrophenyl)-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound CC1=C(C=C(F)C(=C1)[N+]([O-])=O)C1=CCN(CC1)C(=O)OC(C)(C)C URNIKKBMSGLWFT-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RYWJXYWJUJFEMD-UHFFFAOYSA-N 1-bromo-5-fluoro-2-methyl-4-nitrobenzene Chemical compound CC1=CC([N+]([O-])=O)=C(F)C=C1Br RYWJXYWJUJFEMD-UHFFFAOYSA-N 0.000 description 1
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LRJQBZZUYWUWLY-UHFFFAOYSA-N 4-(2-methyl-4-nitro-5-propan-2-yloxyphenyl)-1-(oxan-4-yl)-3,6-dihydro-2H-pyridine Chemical compound CC(C)Oc1cc(C2=CCN(CC2)C2CCOCC2)c(C)cc1[N+]([O-])=O LRJQBZZUYWUWLY-UHFFFAOYSA-N 0.000 description 1
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 description 1
- WCWDGDXBPOYHCT-UHFFFAOYSA-N 5-methyl-4-[1-(oxan-4-yl)-3,6-dihydro-2H-pyridin-4-yl]-2-propan-2-yloxyaniline Chemical compound CC(C)Oc1cc(C2=CCN(CC2)C2CCOCC2)c(C)cc1N WCWDGDXBPOYHCT-UHFFFAOYSA-N 0.000 description 1
- 101150023956 ALK gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229940127513 Fusion Protein Inhibitors Drugs 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 229960001611 alectinib Drugs 0.000 description 1
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229950004272 brigatinib Drugs 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 230000005861 gene abnormality Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- UHNHTTIUNATJKL-UHFFFAOYSA-N n-methylmethanesulfonamide Chemical compound CNS(C)(=O)=O UHNHTTIUNATJKL-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000013126 network meta-analysis Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- the present invention relates to a novel heterocyclic substituted pyrimidine derivative that effectively inhibits the growth of various cancer cells and a pharmaceutical composition containing the same.
- Non-Small Cell Lung Cancer which is caused by various causes, is a disease with a very high cancer-related disease prevalence and mortality.
- Non-small cell lung cancer is mainly caused by mutations or overexpression of tyrosine kinase enzymes, and anticancer drugs developed to date are mainly aimed at inhibiting the activity of cancer-causing enzymes related to these specific mutations.
- the non-small cell lung cancer is caused by mutations in EGFR, known as epidermal growth factor receptor, as well as expression, fusion, rearrangement, etc. of various oncogenes, particularly ALK, KRAS, ROS1, and the like.
- ALK Anaplastic Lymphoma Kinase gene abnormality (EML4-ALK transfusion) is observed in about 12% of NSCLC patients.
- ALK-positive NSCLC is caused by the fusion of ALK and EML4 genes, and the fusion of the two genes is known to accelerate the cell growth rate by the ALK gene, and to rapidly transform cells that have received this signal into cancer cells (tumor cell transformation).
- Crizotinib a first-line treatment for ALK-positive cancer, was approved by the US FDA as a multi-targeted anticancer drug in 2011, and through inhibition of activities such as c-MET, ALK, and ROS1, It is used for the treatment of metastatic, ALK-positive non-small cell lung cancer, etc.
- crizotinib As with other anticancer drugs, the use of crizotinib inevitably results in resistance. Mainly, secondary mutations (about 30%) in the ALK kinase domain, amplification of ALK fusion mutant genes, and activation of bypass signaling processes have been reported. there is.
- crizotinib-resistant patients are using ceritinib, alectinib, and brigatinib as second-line treatment, and patients resistant to second-line treatment are using lolartinib as third-line treatment.
- ALK inhibitors for non-small cell lung cancer A systematic review and network meta-analysis.
- EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.
- An object of the present invention is to provide a heterocyclic substituted pyrimidine derivative containing a novel N-alkylalkylsulfonamide functional group that is effective for the treatment of cancer or proliferative diseases.
- the present invention is a pharmaceutical for the treatment of ALK overexpression, ALK mutation, or EGFR mutation cancer or proliferative disease containing the heterocyclic substituted pyrimidine derivative containing the novel N-alkylalkylsulfonamide functional group It aims to provide a composition.
- Another object of the present invention is to provide a pharmaceutical composition for the treatment of ALK-mutated or EGFR-mutated non-small cell lung cancer.
- a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is provided:
- R 1 is a C1 to C4 alkyl group, a C3 to C6 cycloalkyl group, CF 3 , or NR 8 R 9 , wherein R 8 and R 9 are each independently hydrogen or a C1 to C4 alkyl group;
- R 2 is hydrogen, a C1 to C4 alkyl group, a C3 to C6 cycloalkyl group, or -NR 10 R 11 , wherein R 10 and R 11 are each independently hydrogen or a C1 to C4 alkyl group;
- R 3 is hydrogen or a halogen group
- R 4 is hydrogen, halogen, OH, CN, CF 3 , a C1 to C4 alkoxy group, or a C1 to C4 alkyl group;
- R 5 is a C1 to C4 alkoxy group, a C3 to C6 cycloalkoxy group, a C1 to C4 alkoxy group substituted with CF 3 , a C1 to C4 alkyl group, or a C3 to C6 cycloalkyl group, or a C3 to C6 hetero A cycloalkyl group, wherein the heterocycloalkyl group contains 1 to 3 heteroatoms selected from N, O and S;
- R 6 is hydrogen, a halogen group, a C1 to C4 alkyl group, or a C3 to C6 cycloalkyl group;
- R 1a , R 1b , R 2a , and R 2b are each independently hydrogen, a C1 to C4 alkyl group, or halogen;
- R 7 is hydrogen, a C1 to C4 alkyl group, a C3 to C6 cycloalkyl group, or a C3 to C8 heterocycloalkyl group, wherein the hetero ring contains 1 to 3 heteroatoms selected from N, O and S .
- the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof may be used for treatment of cancer or hyperproliferative diseases.
- compositions for treating cancer or hyperproliferative disease comprising the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier.
- the cancer or hyperproliferative disease may be caused by ALK overexpression, ALK mutation, or EGFR mutation.
- the present invention provides a method for treating an animal suffering from cancer or hyperproliferative disease, comprising administering to the animal an effective amount of the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof.
- the cancer or hyperproliferative disease may be caused by ALK overexpression, ALK mutation, or EGFR mutation.
- novel heterocyclic substituted pyrimidine derivative compound or a pharmaceutically acceptable salt thereof of the present invention effectively inhibits the enzymatic activities of ALK, G120R ALK and L1196M ALK and the enzymatic activities of del19/L858R/T790M EGFR and del19/T790M/C797S .
- novel heterocyclic substituted pyrimidine derivative compound or a pharmaceutically acceptable salt thereof of the present invention effectively inhibits the growth of ALK overexpressing, ALK-mutated, or EGFR-mutated cancer cells. Therefore, it can be usefully used for the treatment of ALK overexpression, ALK mutation, or EGFR mutation cancer or proliferative disease.
- C1 to C4 alkyl group refers to straight-chain and branched hydrocarbon groups having the specified number of carbon atoms.
- the alkyl group may be, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl, and the like.
- C3 to C6 cycloalkyl group may be selected from a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group.
- C1 to C4 alkoxy group may be straight-chain or branched-chain. Specifically, it may be selected from methoxy, ethoxy, n-propoxy, or isopropoxy.
- alkylsulfonyl means alkyl-S(O 2 )-. where alkyl is defined above.
- halogen herein may be selected from F, Cl, Br, or I.
- the present invention relates to a compound represented by Formula 1 below or a pharmaceutically acceptable salt thereof.
- R 1 is a C1 to C4 alkyl group, a C3 to C6 cycloalkyl group, CF 3 , or -NR 8 R 9 , wherein R 8 and R 9 are each independently hydrogen or a C1 to C4 alkyl group;
- R 2 is hydrogen, a C1 to C4 alkyl group, a C3 to C6 cycloalkyl group, or -NR 10 R 11 , wherein R 10 and R 11 are each independently hydrogen or a C1 to C4 alkyl group;
- R 3 is hydrogen or a halogen group
- R 4 is hydrogen, halogen, OH, CN, CF 3 , a C1 to C4 alkoxy group, or a C1 to C4 alkyl group;
- R 5 is a C1 to C4 alkoxy group, a C3 to C6 cycloalkoxy group, a C1 to C4 alkoxy group substituted with CF 3 , a C1 to C4 alkyl group, a C3 to C6 cycloalkyl group, or a C3 to C6 heterocycloalkyl group.
- R 6 is hydrogen, a halogen group, a C1 to C4 alkyl group, or a C3 to C6 cycloalkyl group;
- R 1a , R 1b , R 2a , and R 2b are each independently hydrogen, a C1 to C4 alkyl group, or halogen;
- R 7 is hydrogen, a C1 to C4 alkyl group, a C3 to C6 cycloalkyl group, or a C3 to C8 heterocycloalkyl group, wherein the hetero ring contains 1 to 3 heteroatoms selected from N, O and S .
- R 1 is a C1 to C4 alkyl group, a C3 to C6 cycloalkyl group, or -NR 8 R 9 , wherein R 8 and R 9 are each independently hydrogen or a C1 to C4 alkyl group;
- R 2 is hydrogen, a C1 to C4 alkyl group, or a C3 to C6 cycloalkyl group
- R 3 is hydrogen or a halogen group
- R 4 is hydrogen, halogen, OH, CN, or CF 3 ;
- R 5 is a C1 to C4 alkoxy group, a C3 to C6 cycloalkoxy group, or a C1 to C4 alkoxy group substituted with CF 3 ;
- R 6 is hydrogen, a C1 to C4 alkyl group, or a C3 to C6 cycloalkyl group
- R 1a , R 1b , R 2a , and R 2b are hydrogen
- R 7 is a C3 to C6 cycloalkyl group or a C3 to C8 heterocycloalkyl group, wherein the hetero ring may contain 1 to 3 heteroatoms selected from N, O and S.
- R 1 is a C1 to C4 alkyl group, a C3 to C6 cycloalkyl group, or -NH 2 ;
- R 2 is hydrogen, a C1 to C4 alkyl group, or a C3 to C6 cycloalkyl group
- R 3 is hydrogen
- R 4 is halogen
- R 5 is a C1 to C4 alkoxy group, a C3 to C6 cycloalkoxy group, or a C1 to C4 alkoxy group substituted with CF 3 ;
- R 6 is an alkyl group of C1 to C4;
- R 1a , R 1b , R 2a , and R 2b are hydrogen
- R 7 is a C5 to C8 heterocycloalkyl group, wherein the hetero ring may include one hetero atom selected from O and S.
- the compound of Formula 1 may specifically include the following compounds.
- the compounds represented by Formula 1 of the present invention effectively inhibit the enzymatic activities of ALK, G120R ALK and L1196M ALK and the enzymatic activities of del19/L858R/T790M EGFR and del19/T790M/C797S.
- the compounds represented by Formula 1 of the present invention have very good enzyme inhibitory activity compared to crizotinib.
- the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof of the present invention can be used as a drug capable of treating or preventing cancer or hyperproliferative diseases.
- the cancer or hyperproliferative disease may be a disease caused by ALK overexpression or ALK mutation and a disease caused by EGFR mutation.
- the cancers include liver cancer, gastric cancer, pancreatic cancer, colorectal cancer, leukemia, myeloproliferative/myelodysplastic disease, dermatofibrosarcoma, breast cancer, lung cancer, thyroid cancer, colon cancer, prostate cancer, breast cancer, ovarian cancer, brain tumor, osteosarcoma, and head. It may be selected from the group consisting of cancer of the neck and the like.
- the lung cancer may be small cell lung cancer or non-small cell lung cancer.
- the cancer may be non-small cell lung cancer due to ALK overexpression, ALK mutation, or EGFR mutation, and the cancer may be secondary cancer metastasized to other organs from the various types of cancer.
- the compound represented by Formula I according to the present invention may be used in the form of a pharmaceutically acceptable salt derived from an inorganic or organic acid.
- the salt refers to a salt commonly used in the pharmaceutical industry to which the present invention belongs, specifically, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, or It may be a salt induced by at least one acid selected from toluenesulfonic acid and the like.
- the compounds of the present invention may also be in the form of solvates.
- “Solvate” means one or more solute molecules, ie, a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof; and complexes, or aggregates, formed by one or more solvent molecules.
- Solvates can be complexes or aggregates formed with molecules of various solvents such as, for example, water, methanol, ethanol, isopropanol or acetic acid.
- the compounds of the present invention may also be in the form of their stereoisomers.
- the stereoisomers include all stereoisomers such as enantiomers and diastereomers.
- the compound may be in stereoisomerically pure form or a mixture of one or more stereoisomers, eg a racemic mixture. Separation of specific stereoisomers can be performed by any of the conventional methods known in the art. Some examples of the compounds of the present invention may have greater anticancer effects of certain stereoisomers than their racemic mixtures. In this case, the dosage can be reduced by using a specific stereoisomer. Therefore, cancer can be efficiently treated by isolating specific stereoisomers, such as enantiomers or partial regioisomers, which have a high killing effect on cancer cells.
- the present invention is for treating or preventing cancer or hyperproliferative disease comprising the compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier as the active ingredient.
- a pharmaceutical composition is provided.
- the cancer or hyperproliferative disease may be a disease caused by ALK overexpression or ALK mutation and a disease caused by EGFR mutation.
- composition of the present invention uses the above-mentioned Chemical Formula 1 or a salt thereof as an active ingredient, details common to those described above are omitted to avoid excessive redundancy in the present specification.
- the pharmaceutical composition of the present invention may be formulated according to conventional methods, and may be administered in various oral dosage forms such as tablets, pills, powders, capsules, syrups, emulsions, and microemulsions, or intravenous injection, subcutaneous injection, intramuscular injection, and intraperitoneal injection. It may be formulated into parenteral dosage forms such as injection, transdermal injection, or direct injection into tissue.
- “pharmaceutically acceptable carrier” refers to a material, generally an inactive material, used in combination with an active ingredient to aid application of the active ingredient.
- Such carriers are, for example, fillers, binders, disintegrants, buffers, preservatives, antioxidants, lubricants, flavoring agents, thickeners, coloring agents, emulsifiers, and suspensions. It may contain one or more selected from a topical agent, a stabilizer, a pH adjusting agent, and an isotonic agent.
- the carrier used in the present invention examples include cellulose, calcium silicate, lactose, dextrose, corn starch, sucrose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactant, emulsifier, and suspending agent. , diluents, and the like.
- the carrier includes water, saline, glucose aqueous solution, similar sugar aqueous solution, alcohol, glycol, oil, fatty acid, fatty acid ester, glyceride, surfactant, suspending agent, emulsifying agent etc. can be used.
- the present invention provides a method for preventing or treating diseases by administering the compound of the present invention or a pharmaceutically acceptable salt thereof to a subject in need of prevention or treatment of the above-mentioned diseases.
- the dosage of the pharmaceutical composition of the present invention may vary depending on various factors such as the condition of the patient, the route of administration, and the judgment of the attending physician. Effective doses can be estimated from dose-response curves obtained in vitro or in animal model tests. The ratio and concentration of the compound of the present invention present in the composition to be administered may be determined according to chemical characteristics, route of administration, therapeutic dose, and the like.
- the dose of the pharmaceutical composition of the present invention may be, for example, 0.0001 mg/kg (body weight) to 100 mg/kg (body weight) based on the compound of Formula 1.
- the pharmaceutical composition of the present invention may further include at least one selected from an immunomodulatory agent, a chemo-cancer agent, and an immuno-cancer agent.
- Cytokines suitable for use as the immunomodulatory agent are interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.) , macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), or granulocyte macrophage colony stimulating factor (GM-CSF). may be, but is not limited thereto.
- interleukins e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.
- M-CSF macrophage colony stimulating factor
- TNF tumor necrosis factor
- GM-CSF granulocyte macrophage colony stimulating factor
- the chemotherapy is Gemcitabine, Cytarabine, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Docetaxel, Doxorubicin (Doxorubicin), Etoposide, 5-fluorouracil, irinotecan, Methotrexate, Paclitaxel, Topotecan, Trabectedin, Vincristine ( Vincristine), or vinblastine (Vinbrastine), but is not limited thereto.
- the immune anti-cancer agent is CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), PD-1 (Programmed cell death protein 1), LAG-3 (Lymphocyte Activation Gene-3), TIM-3 (T-cell Immunoglobulin and Mucin Immune checkpoint inhibitor for any one selected from the group consisting of -domain containing-3), T-cell Immunoreptor with IG and ITIM domain (TIGIT), or V-domain Ig Suppressor of T cell Activation (VISTA) It may be, but is not limited thereto.
- the compound represented by Formula 1 according to the present invention may be prepared, for example, by the method of Reaction Scheme 1 below:
- Step A-1 Synthesis of N-methyl-N-(2-nitrophenyl)methanesulfonamide
- Step A-2 Synthesis of N-(2-aminophenyl)-N-methylmethanesulfonamide
- N -Methyl- N- (2-nitrophenyl)methanesulfonamide (1.0 equiv.) is dissolved in methanol, ethyl acetate (1:1) and 10% palladium/charcoal (0.2 equiv.) is added. Stir for 2 hours under hydrogen. After completion of the reaction, it is filtered using Celite. Evaporate the filtrate under reduced pressure. Solidify using ethyl ether and pentane. Filter to obtain the target compound. It is used in the next reaction without separation.
- Step A-3 N-(2-((2,5-dichloropyrimidin-4-yl)amino)phenyl)- N -Synthesis of methylmethanesulfonamide
- Step B-1 Synthesis of tert-butyl 4-(5-fluoro-2-methyl-4-nitrophenyl)-3,6-dihydropyridine-1(2H)-carboxylate
- Step B-2 Synthesis of tert-butyl 4-(5-isopropoxy-2-methyl-4-nitrophenyl)-3,6-dihydropyridine-1(2H)-carboxylate
- Step B-3 Synthesis of 4-(5-isopropoxy-2-methyl-4-nitrophenyl)-1,2,3,6-tetrahydropyridine
- Step B-4 4-(5-isopropoxy-2-methyl-4-nitrophenyl)-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydro synthesis of pyridine
- Example 1 N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2 Preparation of ,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide
- Step B-5 2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)aniline synthesis of
- Example 8 N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2 Preparation of ,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylsulfonamide
- the inhibitory activities of ALK, ALK mutant (ALK(G1202R)), and EGFR mutant (ALK(L1196M)) kinases were measured, and the results are shown in Table 1 below. Measurement of the kinase inhibitory activity was shown by calculating the IC 50 value at the concentration at which each compound inhibited the kinase inhibitory activity. Crizotinib (APG-2449) was used as a control drug.
- Each kinase was incubated in 8 mM MOPS, pH 7.0, 0.2 mM EDTA, 250 ⁇ M KKKGQEEEYVFIE, 1 mM sodium orthovanadate, 5 mM sodium-6-glycerophosphate, 10 mM Magnesium acetate, [ 33 P]-ATP.
- the reaction was progressed by adding the evaluation compound (DMSO solution) and Mg/ATP.
- reaction solution was divided into 0.5% 10uL and spotted on a P30 filtermat.
- the compounds prepared according to the examples of the present invention showed similar inhibitory activity to wild-type ALK kinase compared to APG-2449, but showed very good activity to ALK point mutant kinase. .
- the growth inhibitory effects of ALK-mutated cancer cell lines were measured.
- Anticancer activity was measured using H3122 (EML4-ALK v1) and H2228 (EML4-ALK v3) as ALK mutant cell lines by the following method.
- Gene construction wild type and mutant EGFR were purchased from Addgene. All constructions were retroviral vectors, and viral particles were finally completed for infection.
- EBC lysis buffer 50 mM Tris-HCl [pH 8.0], 120 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 0.3 mM phenylmethylsulfonylfluoride, 0.2 mM sodium orthovanadate, 0.5% NP-40, and 5 U/mL aprotinin was used to prepare cell lysates.
- IC 50 values were calculated at the concentration at which each compound inhibited cell growth by 50%, and the results are shown in Table 2 below.
- APG-2449 was used as a control drug.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
실시예 | ALK | ALK(G1202R) | ALK(L1196M) |
IC50 | IC50 | IC50 | |
1 | 1.1nM | 17.8nM | 0.2nM |
2 | 1.8nM | 25.8nM | 0.6nM |
3 | 0.6nM | 0.7nM | 0.05nM |
4 | 0.9nM | 161nM | 0.3nM |
5 | 3.1nM | 153nM | 0.5nM |
6 | 0.6nM | 254nM | 6.7nM |
7 | 0.5nM | 10.5nM | 0.05nM |
8 | 0.6nM | 17.8nM | 0.07nM |
APG-2449 | 0.8nM | >1,000nM | 0.9nM |
Claims (8)
- 하기 화학식 1로 표시되는 화합물 또는 이의 약학적으로 허용 가능한 염;[화학식 1]상기 화학식 1에서,R1은 C1 내지 C4의 알킬기, C3 내지 C6의 사이클로 알킬기, CF3, 또는 -NR8R9이며, 여기서 R8 및 R9는 각각 독립적으로 수소 또는 C1 내지 C4의 알킬기이고,R2는 수소, C1 내지 C4의 알킬기, C3 내지 C6의 사이클로 알킬기, 또는 -NR10R11이며, 여기서 R10 및 R11은 각각 독립적으로 수소 또는 C1 내지 C4의 알킬기이고,R3는 수소 또는 할로겐기이고,R4는 수소, 할로겐, OH, CN, CF3, C1 내지 C4의 알콕시, 또는 C1 내지 C4의 알킬기이고,R5는 C1 내지 C4의 알콕시기, C3 내지 C6의 사이클로 알콕시기, CF3로 치환된 C1 내지 C4의 알콕시기, C1 내지 C4의 알킬기, C3 내지 C6의 사이클로 알킬기, 또는 C3 내지 C6의 헤테로 사이클로 알킬기이며, 여기서 헤테사이클로 알킬기는 N, O 및 S 중에서 선택되는 1 내지 3개의 헤테로 원자를 포함하고,R6은 수소, 할로겐기, C1 내지 C4의 알킬기, 또는 C3 내지 C6의 사이클로 알킬기이고,R1a, R1b, R2a, 및 R2b는 각각 독립적으로 수소, C1 내지 C4의 알킬기, 또는 할로겐이고,R7은 수소, C1 내지 C4의 알킬기, C3 내지 C6의 사이클로 알킬기, 또는 C3 내지 C8의 헤테로 사이클로 알킬기이고, 여기서 상기 헤테로 고리는 N, O 및 S 중에서 선택되는 1 내지 3개의 헤테로 원자를 포함한다.
- 제1항에 있어서,R1은 C1 내지 C4의 알킬기, C3 내지 C6의 사이클로 알킬기, 또는 -NR8R9이며, 여기서 R8 및 R9는 각각 독립적으로 수소 또는 C1 내지 C4의 알킬기이고,R2는 수소, C1 내지 C4의 알킬기, 또는 C3 내지 C6의 사이클로 알킬기이고,R3는 수소, 또는 할로겐기이고,R4는 수소, 할로겐, OH, CN, 또는 CF3이고,R5는 C1 내지 C4의 알콕시기, C3 내지 C6의 사이클로 알콕시기, 또는 CF3로 치환된 C1 내지 C4의 알콕시기이고,R6은 수소, C1 내지 C4의 알킬기, 또는 C3 내지 C6의 사이클로 알킬기이고,R1a, R1b, R2a, 및 R2b는 수소이고,R7은 C3 내지 C6의 사이클로 알킬기 또는 C3 내지 C8의 헤테로 사이클로 알킬기이며, 여기서 상기 헤테로 고리는 N, O 및 S 중에서 선택되는 1 내지 3개의 헤테로 원자를 포함하는 것인 화학식 1로 표시되는 화합물 또는 이의 약학적으로 허용 가능한 염.
- 제 1항에 있어서,상기 화학식 1의 화합물은 하기 화합물로 이루어진 군으로부터 선택되는 것인 화학식 1로 표시되는 화합물 또는 이의 약학적으로 허용 가능한 염:N-(2-((5-클로로-2-((2-아이소프로폭시-5-메틸-4-(1-(테트라하이드로-2H-파이란-4-일)-1,2,3,6-테트라하이드로피리딘-4-일)페닐)아미노)피리미딘-4-일)아미노)페닐)-N-메틸메탄설폰아마이드,N-(2-((5-클로로-2-((2-아이소프로폭시-5-메틸-4-(1-(테트라하이드로-2H-파이란-4-일)-1,2,3,6-테트라하이드로피리딘-4-일)페닐)아미노)피리미딘-4-일)아미노)페닐)메탄설폰아마이드,N-(2-((5-클로로-2-((2-아이소프로폭시-5-메틸-4-(1-(테트라하이드로-2H-파이란-4-일)-1,2,3,6-테트라하이드로피리딘-4-일)페닐)아미노)피리미딘-4-일)아미노)페닐)-N-메틸사이클로프로판설폰아마이드,N-(2-((5-클로로-2-((2-아이소프로폭시-5-메틸-4-(1-(테트라하이드로-2H-파이란-4-일)-1,2,3,6-테트라하이드로피리딘-4-일)페닐)아미노)피리미딘-4-일)아미노)페닐)-N-메틸프로판-2-설폰아마이드,N-(2-((5-클로로-2-((2-아이소프로폭시-5-메틸-4-(1-(테트라하이드로-2H-파이란-4-일)-1,2,3,6-테트라하이드로피리딘-4-일)페닐)아미노)피리미딘-4-일)아미노)페닐)-N-사이클로프로필메탄설폰아마이드,N-(2-((5-클로로-2-((2-아이소프로폭시-5-메틸-4-(1-(테트라하이드로-2H-파이란-4-일)-1,2,3,6-테트라하이드로피리딘-4-일)페닐)아미노)피리미딘-4-일)아미노)페닐)-N-아아이소프로필메탄설폰아마이드,N-(2-((5-클로로-2-((5-메틸-4-(1-(테트라하이드로-2H-파이란-4-일)-1,2,3,6-테트라하이드로피리딘-4-일)-2-(2,2,2-트리플루오로에톡시)페닐)아미노)피리미딘-4-일)아미노)페닐)-N-메틸메탄설폰아마이드,N-(2-((5-클로로-2-((2-아이소프로폭시-5-메틸-4-(1-(테트라하이드로-2H-파이란-4-일)-1,2,3,6-테트라하이드로피리딘-4-일)페닐)아미노)피리미딘-4-일)아미노)페닐)-N-메틸설폰아마이드.
- 유효성분으로서 제1항의 화학식 1로 표시되는 화합물 또는 이의 약학적으로 허용 가능한 염, 및 약학적으로 허용 가능한 담체를 포함하는 암 또는 과증식성 질환 치료용 약학 조성물.
- 제4항에 있어서,상기 암 또는 과증식성 질환은 ALK 과발현, ALK 변이, 또는 EGFR 변이에 의한 것인, 암 또는 과증식성 질환 치료용 약학 조성물.
- 제5항에 있어서,상기 암은, 간암, 위암, 췌장암, 대장암, 백혈병, 골수증식성/골수이형성 질환, 피부섬유육종, 유방암, 폐암, 갑상선암, 대장암, 전립선암, 유방암, 난소암, 뇌종양, 골육종, 또는 머리와 목의 암인, 암 또는 과증식성 질환 치료용 약학 조성물.
- 제4항에 있어서,상기 암은 ALK 과발현 또는 ALK 변이 비소세포폐암 또는 EGFR 변이 비소세포폐암인, 암 또는 과증식성 질환 치료용 약학 조성물.
- 제4항에 있어서,상기 약학 조성물은 면역조절제, 화학 항암제, 및 면역 항암제 중 선택되는 하나 이상을 추가로 포함하는, 암 또는 과증식성 질환 치료용 약학 조성물.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3238857A CA3238857A1 (en) | 2021-12-09 | 2022-12-09 | Novel heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same |
AU2022404890A AU2022404890A1 (en) | 2021-12-09 | 2022-12-09 | Novel heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same |
CN202280080516.4A CN118355012A (zh) | 2021-12-09 | 2022-12-09 | 表现出癌细胞生长抑制效果的新型杂环取代嘧啶衍生物以及含有其的药物组合物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0175542 | 2021-12-09 | ||
KR20210175542 | 2021-12-09 | ||
KR1020220170783A KR20230087407A (ko) | 2021-12-09 | 2022-12-08 | 암세포 성장 억제 효과를 나타내는 신규 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약학 조성물 |
KR10-2022-0170783 | 2022-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023106881A1 true WO2023106881A1 (ko) | 2023-06-15 |
Family
ID=86731010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/020021 WO2023106881A1 (ko) | 2021-12-09 | 2022-12-09 | 암세포 성장 억제 효과를 나타내는 신규 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약학 조성물 |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2022404890A1 (ko) |
CA (1) | CA3238857A1 (ko) |
WO (1) | WO2023106881A1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008073687A2 (en) * | 2006-12-08 | 2008-06-19 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US20120040955A1 (en) * | 2009-04-14 | 2012-02-16 | Richard John Harrison | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
WO2015158310A1 (zh) * | 2014-04-18 | 2015-10-22 | 山东轩竹医药科技有限公司 | 一种酪氨酸激酶抑制剂及其用途 |
KR20190114910A (ko) * | 2018-03-30 | 2019-10-10 | 한미약품 주식회사 | 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체 |
WO2021190417A1 (zh) * | 2020-03-23 | 2021-09-30 | 齐鲁制药有限公司 | 新型氨基嘧啶类egfr抑制剂 |
KR20220170783A (ko) | 2021-06-23 | 2022-12-30 | 윤동진 | 공유교통 기반 교통수단 추천 서버 및 공유교통 기반 교통수단 추천 프로그램 |
-
2022
- 2022-12-09 WO PCT/KR2022/020021 patent/WO2023106881A1/ko active Application Filing
- 2022-12-09 CA CA3238857A patent/CA3238857A1/en active Pending
- 2022-12-09 AU AU2022404890A patent/AU2022404890A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008073687A2 (en) * | 2006-12-08 | 2008-06-19 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US20120040955A1 (en) * | 2009-04-14 | 2012-02-16 | Richard John Harrison | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
WO2015158310A1 (zh) * | 2014-04-18 | 2015-10-22 | 山东轩竹医药科技有限公司 | 一种酪氨酸激酶抑制剂及其用途 |
KR20190114910A (ko) * | 2018-03-30 | 2019-10-10 | 한미약품 주식회사 | 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체 |
WO2021190417A1 (zh) * | 2020-03-23 | 2021-09-30 | 齐鲁制药有限公司 | 新型氨基嘧啶类egfr抑制剂 |
KR20220170783A (ko) | 2021-06-23 | 2022-12-30 | 윤동진 | 공유교통 기반 교통수단 추천 서버 및 공유교통 기반 교통수단 추천 프로그램 |
Non-Patent Citations (3)
Title |
---|
NATURE REVIEWS CLINICAL ONCOLOGY, vol. 15, 2018, pages 694 - 708 |
ONCOTARGET, vol. 7, no. 1, 2016, pages 1066 - 75 |
PLOS ONE, vol. 15, no. 2, 2020 |
Also Published As
Publication number | Publication date |
---|---|
CA3238857A1 (en) | 2023-06-15 |
AU2022404890A1 (en) | 2024-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2262802B1 (en) | Pim kinase inhibitors and methods of their use | |
WO2019112344A1 (ko) | 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 | |
KR20110058866A (ko) | 비시클릭 키나제 억제제 | |
WO2020149723A1 (ko) | 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2020235902A1 (ko) | 헤테로고리 융합 피리미딘 유도체 및 이의 용도 | |
WO2022107919A1 (ko) | N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2020149715A1 (ko) | 피롤로피리딘 유도체 및 단백질 키나아제 관련 질환의 예방 또는 치료에서의 사용을 위한 이의 용도 | |
WO2022131741A1 (ko) | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 | |
WO2021029665A1 (ko) | Flt3 저해 활성을 갖는 신규한 이미다졸 유도체 및 이의 용도 | |
WO2019035522A1 (ko) | 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물 | |
WO2020262998A1 (ko) | 항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물 | |
WO2023106881A1 (ko) | 암세포 성장 억제 효과를 나타내는 신규 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약학 조성물 | |
WO2018030800A1 (ko) | 단백질 키나아제 저해 활성을 갖는 3,4-다이하이드로피리미도[4,5-d]피리미딘-2(1h)-온 골격의 유레아 화합물 | |
WO2023229430A1 (ko) | 헤테로아릴 유도체 화합물 및 이의 용도 | |
WO2021085888A1 (ko) | 암세포 성장 억제 효과를 나타내는 신규한 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 | |
WO2023211238A1 (ko) | 헤테로아릴 유도체 화합물 및 이의 용도 | |
WO2019156438A1 (en) | Hetero ring-fused phenyl compounds for inhibiting tnik and medical uses thereof | |
WO2021182903A1 (ko) | Pi3 키나아제 저해제 및 btk 저해제를 포함하는 조성물 | |
WO2021201576A1 (ko) | 벤조티아졸 유도체 화합물 | |
EP3386988A1 (en) | Novel dihydropyranopyrimidinone derivatives, and use thereof | |
WO2023063751A1 (ko) | Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도 | |
WO2021125758A1 (ko) | 신규한 중수소 치환 피리미딘 유도체 및 이를 포함하는 약제학적 조성물 | |
WO2023090850A1 (en) | Synergic combination of 2,3-dioxygenase inhibitor and immune checkpoint inhibitor for the treatment of cancer | |
WO2023177233A1 (ko) | 신규한 화합물 및 이의 체크포인트 키나제 2 저해 용도 | |
WO2022182029A1 (ko) | 이미다조피리딘 유도체 및 이를 유효성분으로 함유하는 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22904710 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022404890 Country of ref document: AU Ref document number: AU2022404890 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 3238857 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024010588 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2022404890 Country of ref document: AU Date of ref document: 20221209 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022904710 Country of ref document: EP Ref document number: 2024115648 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022904710 Country of ref document: EP Effective date: 20240709 |
|
ENP | Entry into the national phase |
Ref document number: 112024010588 Country of ref document: BR Kind code of ref document: A2 Effective date: 20240527 |